Full-Time
Biopharmaceuticals for neurology and immunology therapies
$148k - $194.3k/yr
Boston, MA, USA + 2 more
More locations: Raleigh, NC, USA | Atlanta, GA, USA
Hybrid
Hybrid: 40% on-site at Atlanta, Raleigh, or Boston; remote option with up to 20% on-site.
UCB Pharma focuses on developing treatments for severe diseases in neurology and immunology. It discovers, develops, and commercializes novel molecules and generates products aimed at improving patient lives. The company works by researching and developing therapies, integrating patient insights to guide innovation, and investing over a quarter of revenue into scientific research. Its global presence (about 9,000 employees across 40 countries) and €5.3 billion 2023 revenue reflect its scale and commitment to bringing therapies to patients worldwide. UCB differentiates itself by combining direct patient engagement with substantial R&D investment to address unmet needs in neurology and immunology, aiming to transform lives through science and patient care.
Company Size
10,001+
Company Stage
IPO
Headquarters
City of Brussels, Belgium
Founded
1928
Help us improve and share your feedback! Did you find this helpful?
People at UCB Pharma who can refer or advise you
Flexible Work Hours
Hybrid Work Options
Remote Work Options
Paid Vacation
PTO/vacation
Paid Sick Leave
Paid Holidays
Health Insurance
Dental Insurance
Vision Insurance
401(k) Retirement Plan
401(k) Company Match
Wellness Program
Mental Health Support
Conference Attendance Budget
Family Planning Benefits
Fertility Treatment Support
Adoption Assistance
Childcare Support
Home Office Stipend
Phone/Internet Stipend
Professional Development Budget
Stock Options
Company Equity
Hybrid Work Options
Neurona Therapeutics, cell therapy company focused on the development of breakthrough treatments for neurological disorders. Here you'll find information about their funding, investors and team.
UCB investing $2B to build manufacturing facility in Georgia. March 25, 2026 | The belgian drugmaker plans to hire about 330 people at a facility that will use advanced manufacturing technologies including AI, robotics and automation to meet rising demand for key products. This will be UCB's first biologics manufacturing facility in the U.S. UCB is investing $2 billion to build its first biologics manufacturing facility in the U.S., putting down roots in Georgia to support products including the psoriasis drug Bimzelx. Belgium-based UCB unveiled plans to build a biologics manufacturing facility in the U.S. last year. At that time, the drugmaker was undertaking a feasibility study to determine the ideal U.S. location. UCB said it was prioritizing regions with strong talent pipelines, an essential consideration for a company seeking to hire at a time when many businesses are preparing to staff new U.S. production sites. UCB has chosen Gwinnett County, Georgia, on the outskirts of Atlanta as the location of its manufacturing facility, the state's governor announced Tuesday. The company plans to build a 460,000-square-foot plant in the county. UCB's facility will create about 330 permanent manufacturing jobs, plus more than 1,000 construction roles, and will use advanced manufacturing technologies including AI, robotics and automation, the company said. The company is the first global tenant at a 2,000-acre campus that is under construction in Rowen. Officials at the Rowen development said they expect design and construction to take six to seven years. The UCB project follows years of public investment in infrastructure such as water and sewer capacity to get the site ready to host companies. Two new developments for lab and office space are expected to add over 2,000 acres of space in Atlanta to accommodate the life science industry's rapid growth. May 16, 2023 Gwinnett County has committed more than $174 million in incentives such as property tax savings, fee waivers and infrastructure investment to support the project. Georgia Governor Brian Kemp said a team traveled to Belgium to pitch to UCB leaders earlier this year. The efforts have secured the largest capital investment in Gwinnett County's history. UCB's new manufacturing location is about 40 miles from its U.S. headquarters, which is northwest of Atlanta in the city of Smyrna. The presence of the University of Georgia, Emory University, Spelman, Georgia Gwinnett College and Georgia Tech in the region could give UCB the talent pipeline it prioritized in its search for a U.S. manufacturing base. The investment follows calls by the Trump administration for biopharma companies to make medicines in the U.S. UCB also faces pressures to meet demand for Bimzelx, an IL-17A/IL-17F blocker that the FDA approved for use in plaque psoriasis in 2023. U.S. Bimzelx sales increased almost sixfold last year, jumping to almost 1.7 billion euros ($2 billion) to make the autoimmune drug the company's best-selling product. Speaking on an earnings call last month, UCB CEO Jean-Christophe Tellier said the U.S. manufacturing investment will support Bimzelx production. UCB has also scaled up partnerships with contract manufacturers in the U.S.
Georgia trend daily - March 25, 2026. 7 hours ago Staff reports, Gov. Kemp on Tuesday announced that global biopharmaceutical giant UCB, Inc. is planning a significant investment of $2 billion in Georgia to establish its first U.S. pharmaceutical biologics manufacturing facility. The investment will generate 330 new jobs over the next several years at the Rowen Foundation's state-of-the-art, 2,000-acre science and learning campus in Gwinnett County. Loran Smith writes, campus life can be a very good life, and love of alma mater can lead to lifelong commitment to the institution. Lucius Sanford, executive director of the Letterwinner Association at Georgia Tech, is an example of the many college faculty members and employees who are homegrown, and who eventually return to campus and find a way to stay put. March 25, 2026 Atlanta Journal-Constitution Adam Van Brimmer reports, maritime trade is crawling at Georgia's ports, but the state authority that operates the nation's third-busiest cargo terminals isn't throttling back its expansion efforts. Container traffic is flat while wheeled and tracked cargo, such as autos, has experienced a double-digit decline for the fiscal year through February, Ports Authority CEO Griff Lynch told his board of directors Tuesday. March 25, 2026 Georgia Ports Authority Staff reports, the Georgia Ports Authority's new inland port in Gainesville, Ga., opens May 4, 2026, a development GPA says will strengthen Northeast Georgia's attractiveness and business competitiveness. With a direct connection to Savannah's 40 ships per week global ocean carrier network, local manufacturers - including poultry, heavy equipment, and forest product companies - can reach international markets more efficiently. March 25, 2026 Augusta Chronicle Erica Van Buren reports, as Georgia and South Carolina plunge into wildfire season, as recently evidenced by a wildfire in McCormick County this month, leftovers from Hurricane Helene might potentially feed some of the blazes. Hurricane Helene debris remains a concern in parts of Georgia and South Carolina, blocking access for firefighters and hindering wildfire suppression. March 25, 2025 The Brunswick News Taylor Cooper reports, the board of the Brunswick Housing Authority heard a proposal from an affordable housing developer Monday but declined to take action. Board members were interested but wanted more information. March 25, 2026 Columbus Ledger-Enquirer Mark Rice reports, six weeks after a proposed hyperscale data center in northeast Muscogee County was announced by Choose Columbus, the Columbus Consolidated Government hosted an information session in the Psalmond Road Recreation Center to highlight "the benefits", but many residents didn't get answers they sought. March 25, 2026 Milledgeville Union-Recorder Billy Hobbs reports, officials with The Development Authority of Milledgeville-Baldwin County agreed to a Memorandum of Understanding (MOU) on Monday morning with Grenergy USA for the construction of a new solar project. Beaver Creek Solar is slated to be built in the Coopers area of Baldwin County. March 25, 2026 Georgia Recorder Maya Homan reports, sixty miles away at the state Capitol in Atlanta, lawmakers are mulling a proposal to overhaul Georgia's election system ahead of the 2028 presidential election. But in a ballroom in Athens, hundreds of election workers charged with implementing the laws passed by the General Assembly are preparing to uphold Georgia's election laws, whatever those laws may be. March 25, 2026 Georgia Press Zoe Seiler reports that the Georgia General Assembly is considering legislation that would significantly reduce property taxes and create a new local homestead option sales tax to go toward property tax relief. The House advanced House Bill 1116, known as the Homeownership Opportunity and Market Equalization Act of 2026, on Crossover Day, March 6. March 25, 2026 State Affairs Beau Evans reports that a major bill to help children learn how to read is facing sharp scrutiny in the Senate with days left before the 2026 legislative session ends. Backers of the literacy measure have hailed it as a game changer for Georgia schools that have seen years of low scores for third grade students, with key aspects of the proposal centered on hiring more than 1,300 hands-on coaches to work with students and teachers on reading skills. March 25, 2026 Capitol Beat News Ty Tagami reports that a state-funded college scholarship based on financial need rather than academic merit took another step toward becoming a reality in Georgia on Tuesday when a Senate committee approved the bipartisan measure. House Bill 1413 passed the Senate Higher Education Committee unanimously after three other bills were merged with it. March 25, 2026 Atlanta Journal-Constitution Greg Bluestein, Tia Mitchell, Patricia Murphy and Adam Beam report, with airport security lines stretching for hours and the congressional stalemate over Homeland Security funding now in its sixth week, Atlanta's Delta Air Lines is suspending major travel perks for members of Congress. "Due to the impact on resources from the longstanding government shutdown, Delta will temporarily suspend specialty services to members of Congress flying Delta," a Delta statement read.
UCB to invest $2 billion in Georgia, establish first U.S. Manufacturing facility. Wednesday, March 25th, 2026 Governor Brian P. Kemp today announced that global biopharmaceutical giant UCB, Inc. is planning a significant investment of $2 billion in Georgia to establish its first U.S. pharmaceutical biologics manufacturing facility. The investment will generate 330 new jobs over the next several years at the Rowen Foundation's state-of-the-art, 2,000-acre science and learning campus in Gwinnett County. "When we met with UCB leadership earlier this year in Belgium, we discussed how the Peach State would be the right partner for their visionary plans in the U.S. that will benefit both patients and hardworking Georgians," said Governor Brian Kemp. "UCB's announcement is also a significant milestone for our life sciences industry, representing one of the largest investments in state history and establishing both the Rowen facility and Georgia as a true hub of innovation in this field." A global biopharmaceutical company based in Belgium, UCB's North American headquarters are located in Smyrna and currently support more than 400 jobs. UCB's expertise spans neurology and immunology. "This decision reflects our confidence in UCB's long-term growth and our deep-rooted commitment to the United States," said Jean-Christophe Tellier, CEO of UCB. "By investing in Georgia, where our U.S. headquarters have been based for more than three decades, we are strengthening our biologics manufacturing capabilities, supporting our innovation pipeline, and creating high-quality jobs in a state that offers outstanding talent, a strong manufacturing tradition, and an ecosystem designed for sustainable, long-term success. This project is expected to generate approximately $5 billion in total economic impact, reflecting the broader value it will create for the region and its communities." UCB's new manufacturing footprint will be located at Rowen, serving as an anchor tenant for this 2,000-acre planned community in metro Atlanta designed to foster collaboration, knowledge sharing, and innovation. The cutting-edge campus will use a digital-first approach by leveraging AI, robotics, and automation while also prioritizing efficiency in the use of any natural resources. "We are thrilled that UCB has chosen Gwinnett County to advance its global operations and pioneering innovations," said Chairwoman Nicole Love Hendrickson, Gwinnett County Board of Commissioners. "An investment of this magnitude was exactly what we envisioned when we committed to establishing Rowen as a hub for collaboration and discovery. As one of the most dynamic and diverse counties in the nation, Gwinnett connects UCB to a highly skilled, globally connected talent pool. UCB's decision to invest here makes clear what industry leaders increasingly recognize: Gwinnett County is a partner in progress, committed to world-class infrastructure, premier services, and quality of life that support continued growth and success." "UCB's decision to locate their new manufacturing operation in Gwinnett County is a testament to the strength of our entire region to support the growth of the life sciences industry," said Katie Kirkpatrick, President and CEO of the Metro Atlanta Chamber. "UCB's innovation, talent, and strategic investment show that metro Atlanta is not just a hub for life sciences today, but a place where the breakthroughs of tomorrow are taking shape." Project Director EJane Caraway represented the Georgia Department of Economic Development's (GDEcD) Global Commerce team on this competitive project in partnership with Partnership Gwinnett, Metro Atlanta Chamber, Georgia Quick Start, and Georgia Power. "For more than a century, UCB has been a leader in biopharmaceutical innovation," said GDEcD Commissioner Pat Wilson. "Georgia's growing life sciences ecosystem and collaborative approach to economic development connect companies with world-class partners in research, education, logistics, and infrastructure. Together with our focus on being the Top State for Talent, it's why innovators like UCB choose Georgia to advance discoveries from R&D to real-world impact."
UCB to invest $2 billion in Georgia, establish first U.S. Manufacturing facility. March 24, 2026. The Metro Atlanta Chamber celebrates the state's announcement of UCB's first U.S. manufacturing facility. ATLANTA - Governor Brian P. Kemp today announced that global biopharmaceutical giant UCB, Inc. is planning a significant investment of $2 billion in Georgia to establish its first U.S. pharmaceutical biologics manufacturing facility. The investment will generate 330 new jobs over the next several years at the Rowen Foundation's state-of-the-art, 2,000-acre science and learning campus in Gwinnett County. "When we met with UCB leadership earlier this year in Belgium, we discussed how the Peach State would be the right partner for their visionary plans in the U.S. that will benefit both patients and hardworking Georgians," said Governor Brian Kemp. "UCB's announcement is also a significant milestone for our life sciences industry, representing one of the largest investments in state history and establishing both the Rowen facility and Georgia as a true hub of innovation in this field." A global biopharmaceutical company based in Belgium, UCB's North American headquarters are located in Smyrna and currently support more than 400 jobs. UCB's expertise spans neurology and immunology. "This decision reflects our confidence in UCB's long-term growth and our deep-rooted commitment to the United States," said Jean-Christophe Tellier, CEO of UCB. "By investing in Georgia, where our U.S. headquarters have been based for more than three decades, we are strengthening our biologics manufacturing capabilities, supporting our innovation pipeline, and creating high-quality jobs in a state that offers outstanding talent, a strong manufacturing tradition, and an ecosystem designed for sustainable, long-term success. This project is expected to generate approximately $5 billion in total economic impact, reflecting the broader value it will create for the region and its communities." UCB's new manufacturing footprint will be located at Rowen, serving as an anchor tenant for this 2,000-acre planned community in metro Atlanta designed to foster collaboration, knowledge sharing, and innovation. The cutting-edge campus will use a digital-first approach by leveraging AI, robotics, and automation while also prioritizing efficiency in the use of any natural resources. "We are thrilled that UCB has chosen Gwinnett County to advance its global operations and pioneering innovations," said Chairwoman Nicole Love Hendrickson, Gwinnett County Board of Commissioners. "An investment of this magnitude was exactly what we envisioned when we committed to establishing Rowen as a hub for collaboration and discovery. As one of the most dynamic and diverse counties in the nation, Gwinnett connects UCB to a highly skilled, globally connected talent pool. UCB's decision to invest here makes clear what industry leaders increasingly recognize: Gwinnett County is a partner in progress, committed to world-class infrastructure, premier services, and quality of life that support continued growth and success." "UCB's decision to locate their new manufacturing operation in Gwinnett County is a testament to the strength of our entire region to support the growth of the life sciences industry," said Katie Kirkpatrick, President and CEO of the Metro Atlanta Chamber. "UCB's innovation, talent, and strategic investment show that metro Atlanta is not just a hub for life sciences today, but a place where the breakthroughs of tomorrow are taking shape." Project Director EJane Caraway represented the Georgia Department of Economic Development's (GDEcD) Global Commerce team on this competitive project in partnership with Partnership Gwinnett, Metro Atlanta Chamber, Georgia Quick Start, and Georgia Power. "For more than a century, UCB has been a leader in biopharmaceutical innovation," said GDEcD Commissioner Pat Wilson. "Georgia's growing life sciences ecosystem and collaborative approach to economic development connect companies with world-class partners in research, education, logistics, and infrastructure. Together with our focus on being the Top State for Talent, it's why innovators like UCB choose Georgia to advance discoveries from R&D to real-world impact." UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With approximately 9,000 people in approximately 40 countries, the company generated revenue of €7.7 billion in 2025. UCB is listed on Euronext Brussels (symbol: UCB). Follow Metro Atlanta Chamber on Twitter: @UCB_news.